AFG2A
ATPase family gene 2 protein homolog A
Also known as: AFG2, AFG2A_HUMAN, SPAF, SPATA5
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8NB90
- Gene
- AFG2A
- Ensembl
- ENSG00000145375
- Chromosome
- 4
- Canonical length
- 893 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Cytosol
OverviewNCBI Gene
This gene encodes a member of the ATPase associated with diverse activities family, whose members are defined by a highly conserved ATPase domain. Members of this family participate in diverse cellular processes that include membrane fusion, DNA replication, microtubule severing, and protein degradation. The protein encoded by this gene has a putative mitochondrial targeting sequence and has been proposed to function in maintenance of mitochondrial function and integrity during mouse spermatogenesis. Allelic variants in this gene have been associated with epilepsy, hearing loss, and cognitive disability syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2016]
Canonical amino-acid sequenceUniProt
893 residues, UniProt reviewed canonical sequence.
>Q8NB90|AFG2A
1 MSSKKNRKRL NQSAENGSSL PSAASSCAEA RAPSAGSDFA ATSGTLTVTN LLEKVDDKIP
61 KTFQNSLIHL GLNTMKSANI CIGRPVLLTS LNGKQEVYTA WPMAGFPGGK VGLSEMAQKN
121 VGVRPGDAIQ VQPLVGAVLQ AEEMDVALSD KDMEINEEEL TGCILRKLDG KIVLPGNFLY
181 CTFYGRPYKL QVLRVKGADG MILGGPQSDS DTDAQRMAFE QSSMETSSLE LSLQLSQLDL
241 EDTQIPTSRS TPYKPIDDRI TNKASDVLLD VTQSPGDGSG LMLEEVTGLK CNFESAREGN
301 EQLTEEERLL KFSIGAKCNT DTFYFISSTT RVNFTEIDKN SKEQDNQFKV TYDMIGGLSS
361 QLKAIREIIE LPLKQPELFK SYGIPAPRGV LLYGPPGTGK TMIARAVANE VGAYVSVING
421 PEIISKFYGE TEAKLRQIFA EATLRHPSII FIDELDALCP KREGAQNEVE KRVVASLLTL
481 MDGIGSEVSE GQVLVLGATN RPHALDAALR RPGRFDKEIE IGVPNAQDRL DILQKLLRRV
541 PHLLTEAELL QLANSAHGYV GADLKVLCNE AGLCALRRIL KKQPNLPDVK VAGLVKITLK
601 DFLQAMNDIR PSAMREIAID VPNVSWSDIG GLESIKLKLE QAVEWPLKHP ESFIRMGIQP
661 PKGVLLYGPP GCSKTMIAKA LANESGLNFL AIKGPELMNK YVGESERAVR ETFRKARAVA
721 PSIIFFDELD ALAVERGSSL GAGNVADRVL AQLLTEMDGI EQLKDVTILA ATNRPDRIDK
781 ALMRPGRIDR IIYVPLPDAA TRREIFKLQF HSMPVSNEVD LDELILQTDA YSGAEIVAVC
841 REAALLALEE DIQANLIMKR HFTQALSTVT PRIPESLRRF YEDYQEKSGL HTLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AFG2A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.36
- Highest tissue expression
- 3.4 nTPM
Expression across tissuesHPA
Tissue
- testis: 3.4 nTPM
- stomach: 2.2 nTPM
- retina: 2.1 nTPM
- thymus: 1.9 nTPM
- breast: 1.6 nTPM
- adipose tissue: 1.4 nTPM
Single-cell type
- early spermatids: 263 nCPM
- microglia: 241 nCPM
- late primary spermatocytes: 230 nCPM
- megakaryocyte progenitors: 203 nCPM
- erythrocyte progenitors: 186 nCPM
- cone photoreceptor cells: 178 nCPM
Immune cell
- plasmacytoid DC: 0.7 nTPM
- gdT-cell: 0.6 nTPM
- intermediate monocyte: 0.6 nTPM
- basophil: 0.5 nTPM
- memory B-cell: 0.5 nTPM
- memory CD4 T-cell: 0.5 nTPM
Brain region
- cerebellum: 6.6 nTPM
- choroid plexus: 4.7 nTPM
- hypothalamus: 4.7 nTPM
- medulla oblongata: 4.7 nTPM
- pons: 4.7 nTPM
- white matter: 4.6 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about AFG2A.
Disease | AllUniProt
Conditions AFG2A is implicated in, by any mechanism.
- Neurodevelopmental disorder with hearing loss, seizures, and brain abnormalities (NEDHSB) MIM:616577
Disease | GeneticClinVar
100 pathogenic / likely-pathogenic of 911 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome
- Neurodevelopmental disorder
- Inborn genetic diseases
- AFG2A-related disorder
- Syndromic complex neurodevelopmental disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.08
- gnomAD pLI
- 0
- DepMap mean gene effect
- -0.77
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- AAA+ ATPase domain
- ATPase, AAA-type, core
- ATPase, AAA-type, conserved site
- Aspartate decarboxylase-like domain superfamily
- P-loop containing nucleoside triphosphate hydrolase
- AAA ATPase, AAA+ lid domain
- AAA ATPase domain-containing protein
- ATPase family associated with various cellular activities (AAA)
- AAA+ lid domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of AFG2A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AFG2A as an antibody target. Whether an autoantibody or antibody against AFG2A could matter depends on whether native AFG2A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AFG2A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label AFG2A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...